Health Catalyst, Inc.

Report azionario NasdaqGS:HCAT

Capitalizzazione di mercato: US$169.2m

Health Catalyst Crescita futura

Criteri Future verificati 0/6

Si prevede che i ricavi di Health Catalyst diminuiranno a 8.7% all'anno, mentre si prevede che i suoi utili annuali cresceranno a 70.7% all'anno. Si prevede che l'EPS crescerà di 74.9% all'anno. Si prevede che il ritorno sul capitale proprio sarà 5.1% in 3 anni.

Informazioni chiave

70.7%

Tasso di crescita degli utili

74.85%

Tasso di crescita dell'EPS

Healthcare Services crescita degli utili20.9%
Tasso di crescita dei ricavi-8.7%
Rendimento futuro del capitale proprio5.15%
Copertura analitica

Good

Ultimo aggiornamento26 Jun 2026

Aggiornamenti recenti sulla crescita futura

Recent updates

Aggiornamento narrativa • Jul 07

HCAT: Vitalware Sale And Impairment Charges Will Pressure Shares Further

Health Catalyst's analyst price target has shifted to $1.75 from $1, as analysts factor in the pending Vitalware sale and update their assumptions on fair value, discount rate, revenue growth, profit margins, and future P/E multiples. Analyst Commentary Recent Street research on Health Catalyst highlights a mixed picture, with the updated US$1.75 price target reflecting both the pending Vitalware sale and an effort to recalibrate assumptions for fair value, discount rates, revenue growth, margins, and future P/E multiples.
Aggiornamento narrativa • Jun 23

HCAT: Cost Restructuring And Governance Changes Will Shape A Measured Turnaround

Analysts have trimmed their 12 month price target on Health Catalyst by $0.25, citing updated assumptions around fair value, growth expectations, profitability and future P/E multiples. What’s in the News for Health Catalyst Health Catalyst has scheduled its 2026 Annual Meeting of Stockholders for July 16, 2026, to be held via a live interactive audio webcast.
Aggiornamento narrativa • Jun 05

HCAT: Execution On Product Transition And Cost Cuts Will Shape 2026 Reset

Analysts have trimmed Health Catalyst's implied fair value to $2.00 per share from $5.00. This reflects a higher discount rate, a cut to longer term revenue expectations after softer Q1 guidance and a delayed FY26 outlook, and lower assumed future P/E multiples despite relatively stable profit margin assumptions.
Aggiornamento narrativa • May 09

HCAT: New Leadership And AI Investments Will Drive Post Review Turnaround

Narrative Update on Health Catalyst The updated analyst price target for Health Catalyst has shifted lower toward a cluster around $2, reflecting analyst caution after reduced targets and commentary around softer near term guidance, the ongoing transition from DOS to Ignite, and the company’s current strategic and operational reviews. Analyst Commentary Recent research reflects a cautious stance on Health Catalyst, with price targets clustered in the US$1.75 to US$3.00 range and several firms highlighting execution risk around guidance, product transition, and ongoing reviews.
Aggiornamento narrativa • Apr 24

HCAT: Guidance Reset And Impairment Charges Will Pressure Shares Further

Analyst price targets on Health Catalyst have been reset lower to a range of roughly $1.75 to $3, reflecting concerns about Q1 guidance, delayed FY26 outlook, product transition risks, and the need for more proof that the new leadership and AI-focused investments can gain traction. Analyst Commentary Recent Street research on Health Catalyst reflects a cautious reset in expectations, with multiple bearish analysts trimming price targets into a tighter US$1.75 to US$3 band and emphasizing execution and growth risks.
Aggiornamento narrativa • Apr 08

HCAT: Earnings Uncertainty And Platform Transition Will Drive Further Downside Risk

Narrative Update on Health Catalyst The updated analyst price target for Health Catalyst has shifted sharply lower, with several firms cutting targets into a $1.75 to $3 range. Analysts are factoring in higher perceived risk, softer revenue and margin assumptions, and the earnings impact of the DOS to Ignite transition and the ongoing strategic review.
Aggiornamento narrativa • Mar 25

HCAT: New Leadership And AI Investments Will Set Up 2026 Rebound

Analysts have reduced the base case price target on Health Catalyst from $3.88 to $2.09. The revision reflects a series of lower Street targets tied to softer near term growth assumptions, a higher discount rate, and calls for more clarity around the company’s product transition and ongoing reviews.
Aggiornamento narrativa • Mar 11

HCAT: Lowered Sector Outlook Will Set Up Cautiously Optimistic 2026 Rebound

Analysts have trimmed their price target on Health Catalyst by $0.50 to $2.75. This reflects a more cautious view on near term sector challenges, while they maintain a neutral stance on the shares.
Aggiornamento narrativa • Feb 24

HCAT: Cautiously Higher Future P/E And Reset Expectations Support Upside Potential

Analysts have trimmed their price target on Health Catalyst to $2.75 from $3.25, reflecting more cautious assumptions around revenue growth and risk, while remaining generally constructive on the sector heading into 2026. Analyst Commentary Bullish Takeaways Bullish analysts point to the lower US$2.75 target as still implying some value in Health Catalyst's data and analytics platform relative to current trading levels, even after a tough 2025 for the group.
Articolo di analisi • Feb 13

Improved Revenues Required Before Health Catalyst, Inc. (NASDAQ:HCAT) Shares Find Their Feet

With a price-to-sales (or "P/S") ratio of 0.4x Health Catalyst, Inc. ( NASDAQ:HCAT ) may be sending bullish signals at...
Aggiornamento narrativa • Feb 10

HCAT: Lower 2025 Expectations Will Set Up Cautiously Optimistic 2026 Rebound

Analysts have trimmed their price expectations for Health Catalyst, with the latest target moving from US$3.25 to US$2.75 as they factor in what they describe as a challenging 2025 for health tech and a cautious outlook into 2026. Analyst Commentary Even with the lower target, bullish analysts see reasons to stay engaged with Health Catalyst, especially as the sector works through what they describe as a tough patch in 2025 and looks ahead to 2026.
Aggiornamento narrativa • Jan 27

HCAT: Cautiously Higher Future P/E And Stable Margins Support Upside Potential

Analysts have trimmed their 12 month price target on Health Catalyst by $0.50 to $2.75, citing tougher assumptions around growth and margins, balanced by a slightly higher future P/E multiple and an updated risk outlook. Analyst Commentary Bullish Takeaways Bullish analysts point out that the revised US$2.75 target still reflects some confidence that the current valuation already prices in a tough recent period for health tech.
Aggiornamento narrativa • Jan 10

HCAT: Cautious Sector Reset Will Still Support Future Revenue Visibility

Analysts have reduced their price target on Health Catalyst to $2.75 from $3.25, reflecting more cautious assumptions on revenue growth and margins, while maintaining a neutral stance on the stock. Analyst Commentary Bullish analysts are framing the lower US$2.75 price target as a recalibration rather than a shift in overall stance, with the neutral rating indicating that they see the current share price as broadly in line with their updated expectations.
Aggiornamento narrativa • Dec 26

HCAT: Rising Discount Rate Will Still Support Strong Future Revenue Visibility

Analysts have reduced their price target on Health Catalyst by approximately $1.00 per share. This change reflects updated assumptions for a higher discount rate, slower revenue growth, and more muted profit margin and valuation expectations.
Aggiornamento narrativa • Dec 11

HCAT: Stable Margins And Revenue Outlook Will Support Future Upside Potential

Narrative Update on Health Catalyst Analyst Price Target Analysts have modestly raised their price target on Health Catalyst by approximately 4 percent to around 3.94 dollars. This reflects slight adjustments to the discount rate and future earnings expectations, while views on revenue growth and profit margins remain largely unchanged.
Aggiornamento narrativa • Nov 27

HCAT: Customer Partnerships Will Support Performance Despite Revised 2025 Revenue Outlook

Analysts have modestly lowered their price target for Health Catalyst. This adjustment is due to a slightly reduced profit margin outlook and a more conservative future price-to-earnings ratio, reflecting updated expectations for the company’s financial performance.
Aggiornamento narrativa • Nov 13

HCAT: Ongoing Customer Relationships Will Drive Performance Amid Lower Revenue Guidance

Analysts have lowered their price target for Health Catalyst from $8 to $4. They cite recent reductions in revenue guidance, as well as expectations for lower growth and profitability.
Articolo di analisi • Oct 28

Improved Revenues Required Before Health Catalyst, Inc. (NASDAQ:HCAT) Shares Find Their Feet

You may think that with a price-to-sales (or "P/S") ratio of 0.8x Health Catalyst, Inc. ( NASDAQ:HCAT ) is definitely a...
Aggiornamento narrativa • Aug 30

Modular AI Solutions Will Transform Value-Based Healthcare

Health Catalyst's price target has been cut as analysts cite persistent operating headwinds, declining revenue outlook, customer churn, market structural challenges, and heightened uncertainty from a CEO transition, resulting in a downward revision of fair value from $5.33 to $4.56. Analyst Commentary Weak first-half 2025 bookings and a reduction in revenue guidance, implicating lower net revenue retention and increased customer churn.
Articolo di analisi • Aug 13

Health Catalyst, Inc. (NASDAQ:HCAT) Just Reported Earnings, And Analysts Cut Their Target Price

NasdaqGS:HCAT 1 Year Share Price vs Fair Value Explore Health Catalyst's Fair Values from the Community and select...
Aggiornamento narrativa • Aug 10

Modular AI Solutions Will Transform Value-Based Healthcare

Health Catalyst’s consensus price target has been reduced to $5.78, primarily reflecting a deterioration in net profit margin despite a lower discount rate. What's in the News CEO Dan Burton will step down effective June 2026, transitioning from his full-time role while continuing to assist the Board and serve as a director.
Articolo di analisi • Aug 04

Is Health Catalyst (NASDAQ:HCAT) Using Too Much Debt?

Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
Seeking Alpha • Jun 10

Health Catalyst: Ignite Platform Is A Growth Catalyst

Summary I rate Health Catalyst a buy, driven by strong turnaround momentum and the transformative Ignite platform fueling faster growth and higher margins. Ignite's modular, lower-cost structure accelerates sales cycles, improves gross margins, and opens significant upsell opportunities within HCAT’s large existing customer base. Recent financials show accelerating revenue growth and strong client additions, supporting management’s FY25 guidance and signaling a potential inflection point for the business. Read the full article on Seeking Alpha
Articolo di analisi • May 09

Health Catalyst, Inc. (NASDAQ:HCAT) Just Released Its First-Quarter Results And Analysts Are Updating Their Estimates

It's been a good week for Health Catalyst, Inc. ( NASDAQ:HCAT ) shareholders, because the company has just released its...
User avatar
Nuova narrativa • Mar 30

Ignite Transition And Recent Acquisitions Will Expand Global Footprint

Cross-selling through the Ignite platform is projected to boost client additions and accelerate revenue growth.
Seeking Alpha • Mar 25

Health Catalyst: Share Price Continues To Dismiss Positive Earnings And Improved Outlook

Summary Despite a 50% drop in HCAT's stock price, the company shows significant growth, reporting $307M in revenue and $26M in adjusted EBITDA for 2024. Health Catalyst focuses on efficiency, exiting lower-margin segments, and pushing AI-driven efficiencies, aiming for improved margins and profitability in 2025. The company forecasts strong growth with 40 new platform clients in 2025 and expects $335M in revenue, trading at a significant discount compared to industry peers. Risks include potential revenue stall, macroeconomic challenges, and stock price volatility, but I remain cautiously optimistic, looking for a breakout to add to my position. Read the full article on Seeking Alpha
Articolo di analisi • Mar 08

Take Care Before Jumping Onto Health Catalyst, Inc. (NASDAQ:HCAT) Even Though It's 27% Cheaper

To the annoyance of some shareholders, Health Catalyst, Inc. ( NASDAQ:HCAT ) shares are down a considerable 27% in the...
Articolo di analisi • Feb 27

Health Catalyst (NASDAQ:HCAT) Has Debt But No Earnings; Should You Worry?

The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...

Previsioni di crescita degli utili e dei ricavi

NasdaqGS:HCAT - Stime future degli analisti e dati finanziari passati (USD Millions )
DataRicaviUtiliFlusso di cassa liberoLiquidità dell'operazioneAvg. Numero di analisti
12/31/2028247-58N/AN/A2
12/31/2027247-57N/AN/A6
12/31/2026263-155N/AN/A6
3/31/2026302-265-319N/A
12/31/2025311-178-211N/A
9/30/2025316-108-33-13N/A
6/30/2025316-100-26-6N/A
3/31/2025311-73-145N/A
12/31/2024307-70-215N/A
9/30/2024302-79-16-1N/A
6/30/2024299-86-17-4N/A
3/31/2024297-106-31-17N/A
12/31/2023296-118-47-33N/A
9/30/2023290-124-44-29N/A
6/30/2023285-147-61-44N/A
3/31/2023282-148-59-42N/A
12/31/2022276-137-53-35N/A
9/30/2022272-151-47-30N/A
6/30/2022265-145-40-24N/A
3/31/2022254-147-34-19N/A
12/31/2021242-153-42-23N/A
9/30/2021230-147-39-17N/A
6/30/2021216-135-36-17N/A
3/31/2021200-126-29-13N/A
12/31/2020189-115-37-26N/A
9/30/2020179-86-39-35N/A
6/30/2020171-99-41-36N/A
3/31/2020165-181-48-44N/A
12/31/2019155-241N/A-32N/A
9/30/2019148-304N/A-32N/A
6/30/2019141-282N/A-33N/A
3/31/2019127-190N/A-38N/A
12/31/2018113-114N/A-40N/A
12/31/201773-59N/A-37N/A

Previsioni di crescita futura degli analisti

Guadagni vs tasso di risparmio: Si prevede che HCAT rimarrà non redditizia nei prossimi 3 anni.

Guadagni vs Mercato: Si prevede che HCAT rimarrà non redditizia nei prossimi 3 anni.

Guadagni ad alta crescita: Si prevede che HCAT rimarrà non redditizia nei prossimi 3 anni.

Ricavi vs Mercato: Si prevede che i ricavi di HCAT diminuiranno nei prossimi 3 anni ( -8.7% all'anno).

Ricavi ad alta crescita: Si prevede che i ricavi di HCAT diminuiranno nei prossimi 3 anni ( -8.7% all'anno).

Previsioni di crescita dell'utile per azione

Rendimento futuro del capitale proprio

ROE futuro: Si prevede che il Return on Equity di HCAT sarà basso tra 3 anni ( 5.1 %).

Scoprire le aziende in crescita

7D

1Y

7D

1Y

7D

1Y

Analisi aziendale e situazione dei dati finanziari

DatiUltimo aggiornamento (ora UTC)
Analisi dell'azienda2026/07/15 01:09
Prezzo dell'azione a fine giornata2026/07/15 00:00
Utili2026/03/31
Utili annuali2025/12/31

Fonti dei dati

I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC. I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.

PacchettoDatiTempisticaEsempio Fonte USA *
Dati finanziari della società10 anni
  • Conto economico
  • Rendiconto finanziario
  • Bilancio
Stime di consenso degli analisti+3 anni
  • Previsioni finanziarie
  • Obiettivi di prezzo degli analisti
Prezzi di mercato30 anni
  • Prezzi delle azioni
  • Dividendi, scissioni e azioni
Proprietà10 anni
  • Top azionisti
  • Insider trading
Gestione10 anni
  • Team di leadership
  • Consiglio di amministrazione
Sviluppi principali10 anni
  • Annunci aziendali

* Esempio per i titoli statunitensi, per i titoli non statunitensi si utilizzano forme e fonti normative equivalenti.

Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più.

Modello di analisi e Snowflake

I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina GitHub; abbiamo anche delle guide su come utilizzare i nostri report e dei tutorial su YouTube.

Scoprite il team di livello mondiale che ha progettato e realizzato il modello di analisi Simply Wall St.

Metriche di settore e industriali

Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su Github.

Fonti analitiche

Health Catalyst, Inc. è coperta da 16 analisti. 6 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.

AnalistaIstituzione
Zhilin LongBerenberg
David LarsenBTIG
Richard CloseCanaccord Genuity